Evista Prices

EVISTA

Evista is a registered trademark of Eli Lilly and Co. It works primarily by reducing bone loss and is used to treat or prevent osteoporosis in women after menopause.

Buy Evista without prescription – Indications

Evista is used to prevent and treat bone loss or osteoporosis in women after the age of menopause. Maintaining strong bones by slowing down bone loss helps reduce the risk of fractures. Evista or Raloxifene may also decrease the chances of getting some type of breast cancer in women after menopause. This medicine is different from hormones as well as estrogen and progestins. It functions as estrogen (estrogen receptor specific modulator or SERM) in certain parts of the body. Evista helps preserve bone mass, but it has no effect on breast and uterine cancer such as estrogen or so relieve menopausal symptoms like hot flashes. This medication is not recommended for use in women who have not yet reached menopause. It should not be used in children either. This medication should not be used to prevent heart disease.

Dosage Raloxifene 

Read the package leaflet carefully before using it. If you have questions, talk to your doctor or pharmacist. Take this medicine orally, once a day, with or without food as directed by your doctor. Use this medication regularly to get the best results. Do not forget to use it at the same time each day. Make the maximum effort to include an adequate amount of calcium and vitamin D in your diet. Consult your doctor or pharmacist to find out if you should take calcium / vitamin D supplements. Since this medicine can be absorbed through the skin and lungs and can harm the fetus, pregnant women should not handle this medication. .

Possible side effects evita 60mg

Do not hesitate to seek emergency medical help if you notice or experience any of the following signs of an allergic reaction:

Difficulty breathing swelling of the face, lips, tongue or throat. Call your doctor immediately if you have any serious side effects such as: numbness or sudden weakness, especially on one side of the body; sudden headaches, confusion, vision, speech, or balance problems; chest pain, sudden cough, wheezing, rapid breathing, rapid heartbeat; pain or swelling in one or both legs; swelling of your hands or feet; fever, chills, sore throat, muscle aches, flu symptoms; unusual vaginal bleeding; chest pain, tenderness, or lump; pain or burning when you urinate; or pain in the lower back.

Less serious side effects may manifest as hot flashes; headache, dizziness, feeling of rotation; leg pain; articular pain; increased perspiration; nausea, vomiting, stomach pain; or runny or stuffy nose. This list of adverse effects is far from exhaustive, contact your doctor immediately if you notice any unusual or disturbing signs.

EVISTA (raloxifene) should not be used for primary or secondary prevention of cardiovascular disease. In clinical trials with postmenopausal women with coronary heart disease or increased risk of coronary heart disease, no cardiovascular benefit has been demonstrated after 5 years of raloxifene therapy.

Venous thromboembolism in clinical trials. Women treated with Evista (raloxifene) had increased risk of deep venous thromboembolism and pulmonary embolism, and it was also noted that other venous thromboembolic events could also occur. Some less severe events of superficial thrombophlebitis, were also more frequently reported with EVISTA (raloxifene). The greatest risk of deep vein thrombosis and pulmonary embolism occurs during the first 4 months of treatment, and the magnitude of risk appears to be similar to that reported with the use of hormonal therapy. Because immobilization increases the risk of venous thromboembolic events, and in this case, irrespective of the therapy applied, EVISTA should be discontinued at least 72 hours before and during prolonged immobilization (eg recovery). During recovery, post-surgical, prolonged bed rest), Evista therapy should be resumed only after the patient is fully buying outpatient treatment. Moreover, women undergoing treatment at the Evista must be regularly invited to travel or to travel. The benefit-risk ratio should be considered in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy. Stroke deaths in clinical trials in postmenopausal women with coronary artery disease or at increased risk of coronary heart disease. An increased risk of death from stroke was observed after treatment with EVISTA. The risk-benefit ratio should be considered in women who are at risk for stroke, since stroke is primarily a transient ischemic attack (TIA), as is atrial fibrillation, hypertension, or smoking [see Clinical Studies]. ]. There is no indication for premenopausal use of EVISTA. The reliability and safety of EVISTA in premenopausal women has not been established and its use is not recommended. EVISTA should be used with caution in patients with moderate or severe renal impairment, hepatic impairment, and systemic estrogens as safety and efficacy have not been established in these patients.

Raloxifene price interactions

Concomitant administration of cholestyramine with EVISTA (raloxifene) is not recommended. Although not specifically studied, it is expected that other anion exchange resins would have a similar effect. EVISTA (raloxifene) should not be co-administered with other anion exchange resins.

Warfarin: If EVISTA (raloxifene) is given in combination with warfarin or other coumarin derivatives, the prothrombin time should be monitored more closely when starting or stopping EVISTA.

High Protein Drugs: EVISTA (raloxifene) should be used with caution with some other highly protein drugs such as diazepam, diazoxide, and lidocaine. Although not examined, EVISTA (raloxifene) could affect the binding of other protein drugs. Raloxifene is more than 95% bound to plasma proteins.

Systemic estrogens: The safety of concomitant use of EVISTA (raloxifene) with systemic estrogens has not been established and its use is not recommended. This medication can be co-administered with ampicillin, amoxicillin, antacids, corticosteroids and digoxin. It should be noted that the concomitant use of EVISTA (raloxifene) and lipid-lowering agents has not been studied.